These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27721664)

  • 1. Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
    Al-Dewik NI; Morsi HM; Samara MM; Ghasoub RS; Gnanam CC; Bhaskaran SK; Nashwan AJ; Al-Jurf RM; Ismail MA; AlSharshani MM; AlSayab AA; Ben-Omran TI; Khatib RB; Yassin MA
    Clin Med Insights Oncol; 2016; 10():95-104. PubMed ID: 27721664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
    Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
    Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
    Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
    Lam MS; Cheung N
    J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
    Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
    Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Pennisi MS; Stella S; Vitale SR; Puma A; Di Gregorio S; Romano C; Tirrò E; Massimino M; Antolino A; Siragusa S; Mannina D; Impera S; Musolino C; Mineo G; Martino B; Zammit V; Di Raimondo F; Manzella L; Stagno F; Vigneri P
    Front Oncol; 2019; 9():764. PubMed ID: 31456947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
    de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
    Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib.
    Omran MM; Ibrahim AB; Abdelfattah R; Moussa HS; Shouman SA; Hamza MS
    Leuk Lymphoma; 2024 Sep; ():1-8. PubMed ID: 39291898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
    Haque R; Shi J; Chung J; Xu X; Avila C; Campbell C; Ahmed SA; Chen L; Schottinger JE
    J Am Pharm Assoc (2003); 2017; 57(3):303-310.e2. PubMed ID: 28259737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia.
    Krützmann ME; Martini RR; de Souza Guterres F; Kohlrausch R; Wagner SC; Mattevi VS; Torriani MS; Fogliatto LM; Linden R; Antunes MV
    J Pharm Biomed Anal; 2023 Jan; 222():115108. PubMed ID: 36279845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells.
    Flis S; Bratek E; Chojnacki T; Piskorek M; Skorski T
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
    Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
    Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
    Jönsson S; Olsson B; Söderberg J; Wadenvik H
    Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
    Santoleri F; Lasala R; Ranucci E; La Barba G; Di Lorenzo R; Vetrò A; Di Bartolomeo P; Costantini A
    Acta Haematol; 2016; 136(1):45-51. PubMed ID: 27160310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
    Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
    Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.